Table 2 Baseline characteristics of controls, pre-HF patients, and HFpEF patients in the Belgian and the Beta3-LVH cohorts
Belgian cohort | Beta3-LVH cohort | Belgian cohort | Belgian cohort | |
|---|---|---|---|---|
Controls | Pre-HF | Pre-HF | HFpEF | |
N = 26 | N = 191 | N = 16 | N = 104 | |
Age (years) | 76 ± 5 | 64 ± 10 | 75 ± 4 | 77 ± 8 |
Female (n, %) | 17 (65.4%) | 53 (27.7%) | 10 (62.5%) | 58 (55.8%) |
BMI (kg/m2) | 25.5 ± 3.3 | 29.8 ± 4.41 | 27.2 ± 4.2 | 28.9 ± 6.6 |
Diabetes (n, %) | 3 (11.5%) | 37 (19.4%) | 4 (26.7%) | 44 (42.3%) |
Atrial fibrillation (n, %) | 1 (3.9%) | 3 (1.6%) | 3 (18.8%) | 62 (59.6%) |
eGFR (mL/min/1.73m2) by CK-EPI | 71.0 [54.5–80.8] | 78.2 [69.9–91.0] | 57.0 [49.5–68.5] | 55.0 [40.8–67.0] |
LA volume indexed (ml/m2) by Echo | 19.0 ± 5.9 | 34.0 ± 11.0 | 30.7 ± 10.4 | 44.2 ± 19.1 |
LV ejection Fraction (%) by Echo | 64.9 ± 5.3 | 63.0 ± 6.0 | 66.6 ± 5.6 | 62.6 ± 7.2 |
LV mass indexed (g/m2) by CMR | 59.1 ± 12.1 | 58.0 ± 7.0 | 58.8 ± 12.1 | 67.7 ± 15.4 |
E/e’ ratio | 9.7 ± 1.8 | 9.3 ± 3.1 | 17.1 ± 5.4 | 17.7 ± 6.9 |
H2FPEF Score | 2.2 ± 1.0 | 3.1 ± 1.4 | 4.3 ± 1.4 | 6.0 ± 1.8 |
Indexed EAT volume (ml/m2) | 48.0 ± 8.9 | 52.0 ± 15.0 | 55.0 ± 11.8 | 72.4 ± 20.8 |